drugset / Trial / NCT07660081

Effects of Acetyl L-Carnitine Supplementation on Clinical, Metabolic and Inflammatory Symptoms in Obese, Diabetic, Postmenopausal Women With Osteoarthritis

NCT07660081

Active not recruiting 100 enrolled Khyber Medical University Peshawar
RandomizedParallel-groupDouble-blindTreatment

Summary

OA is a degenerative bone disease more common in postmenopausal women. Diabetes and obesity are common risk factors for the development of OA. The common symptoms include pain and disability of the affected joint, leading to mobility issues. Acetyl L-carnitine due to its known anti-inflammatory, chondroprotective, and improved insulin-sensitizing effects may help in alleviating the symptoms and progression of OA in obese diabetic postmenopausal women.

Timeline

Start
2025-11-01
Primary completion
2026-07-30
Completion
2026-08-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetylcarnitine Small molecule 1.5 g Oral